GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease

Sex-Related Abnormalities in Substantia Nigra Lipids in Parkinson’s Disease

(2018) T. N. Seyfried et al.   ASN Neuro

Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations

(2018) Anthony E. Lang et al.   MOVEMENT DISORDERS

Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression

(2018) Alexander B. Pupyshev et al.   NEUROSCIENCE LETTERS

Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson’s disease

(2018) Jay S. Schneider   PLoS One

Enhanced Autophagy Contributes to Protective Effects of GM1 Ganglioside Against Aβ1-42-Induced Neurotoxicity and Cognitive Deficits

(2017) Ruwei Dai et al.   NEUROCHEMICAL RESEARCH

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease

(2017) Chi Wang Ip et al.   Acta Neuropathologica Communications

Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates

(2017) Shigeki Arawaka et al.   Acta Neuropathologica Communications

GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model

(2015) Piotr Hadaczek et al.   EXPERIMENTAL NEUROLOGY

GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding

(2015) Jay S. Schneider et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Gangliosides: glycosphingolipids essential for normal neural development and function

(2015) Cara-Lynne Schengrund   TRENDS IN BIOCHEMICAL SCIENCES

N-Alpha-Acetylation of α-Synuclein Increases Its Helical Folding Propensity, GM1 Binding Specificity and Resistance to Aggregation

(2014) Tim Bartels et al.   PLoS One

TFEB-mediated autophagy rescues midbrain dopamine neurons from  -synuclein toxicity

(2013) M. Decressac et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans

(2012) Gusheng Wu et al.   JOURNAL OF NEUROSCIENCE RESEARCH

A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients

(2012) Jay S. Schneider et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

GDNF fails to exert neuroprotection in a rat  -synuclein model of Parkinson's disease

(2011) M. Decressac et al.   BRAIN

Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein

(2011) James B. Koprich et al.   PLoS One

Lipid rafts: Keys to neurodegeneration

(2010) Cara-Lynne Schengrund   BRAIN RESEARCH BULLETIN

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease

(2010) James B Koprich et al.   Molecular Neurodegeneration

Protective Role of Endogenous Gangliosides for Lysosomal Pathology in a Cellular Model of Synucleinopathies

(2009) Jianshe Wei et al.   AMERICAN JOURNAL OF PATHOLOGY

Targets for neuroprotection in Parkinson's disease

(2008) Talene A. Yacoubian et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE